All In Biotech

Drug Trial Radar · NCT00350636

A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo

Multi-Center, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Dosing With Oxybutynin Topical Gel to Treat the Symptoms of Overactive Bladder With a 14-Week Open-Label Safety Extension

Last checked: Nov 20, 2026Latest source record: May 10, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 789 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

789

Actual

Start

Jun 2006

Primary completion

May 2007

Study completion May 2007

Sponsor

Lead sponsor
Watson PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jul 11, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A new drug for overactive bladder is compared to placebo to determine if it is safe and effective. The study lasts approximately 12 weeks.

Conditions

  • Overactive Bladder

Interventions

  • Oxybutynin topical gelDrug

    1 application daily to skin for 12 weeks

  • Placebo topical gelOther

    1 application daily to skin for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Baseline Average Number of Daily Incontinence EpisodesTime frame: Baseline
  2. Change From Baseline in Average Daily Number of Incontinence EpisodesTime frame: Baseline to Week 12

Locations

63 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Homewood, Alabama

  • Site not named

    Mobile, Alabama

  • Site not named

    Montgomery, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Anaheim, California

  • Site not named

    Buena Park, California

  • Site not named

    Laguna Woods, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    Torrance, California

  • Site not named

    Denver, Colorado

  • Site not named

    Waterbury, Connecticut

  • Site not named

    Aventura, Florida

  • Site not named

    Clearwater, Florida

  • Site not named

    DeLand, Florida

  • Site not named

    Leesburg, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    Plantation, Florida

  • Site not named

    Tallahassee, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Alpharetta, Georgia

  • Site not named

    Atlanta, Georgia

  • Site not named

    Belville, Illinois

  • Site not named

    Chicago, Illinois

  • Site not named

    Melrose Park, Illinois

  • Site not named

    Evansville, Indiana

  • Site not named

    South Bend, Indiana

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Watertown, Massachusetts

  • Site not named

    Saginaw, Michigan

  • Site not named

    Saint Joseph, Michigan

  • Site not named

    Omaha, Nebraska

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    Albany, New York

  • Site not named

    Garden City, New York

  • Site not named

    New York, New York

Showing 40 of 63 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.